Premium
DEVELOPMENT OF NOVEL, NON‐TOXIC RIFAMYCINS THAT REVERSE DRUG RESISTANCE IN DIFFUSE LARGE B‐CELL LYMPHOMA (DLBCL)
Author(s) -
Maxwell S.A.,
Wallis D.,
Zhou N.,
Baker D.,
MousaviFard S.,
Loesch K.,
Galaviz S.,
Sun Q.,
Threadgill D.M.,
Rojas C.M.,
O'Brien M.,
Clubb F.J.,
Ioerger T.,
DeJesus M.,
Dong W.,
Seemann G.,
Fossum T.,
Sacchettini J.C.
Publication year - 2017
Publication title -
hematological oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.918
H-Index - 44
eISSN - 1099-1069
pISSN - 0278-0232
DOI - 10.1002/hon.2438_118
Subject(s) - medicine , diffuse large b cell lymphoma , chop , pharmacology , vincristine , daunorubicin , doxorubicin , lymphoma , cancer research , oncology , chemotherapy , cyclophosphamide